Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease

Crizanlizumab is an anti–P-selectin monoclonal antibody indicated to reduce the frequency/prevent recurrence of vaso-occlusive crises (VOCs) in patients with sickle cell disease (SCD) aged ≥16 years. This analysis of an ongoing phase 2, nonrandomized, open-label study reports the pharmacokinetics (P...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanter, Julie, Brown, R. Clark, Norris, Cynthia, Nair, Santosh M., Kutlar, Abdullah, Manwani, Deepa, Shah, Nirmish, Tanaka, Chiaki, Bodla, Shankaranand, Sanchez-Olle, Gessami, Albers, Urs, Liles, Darla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027508/
https://www.ncbi.nlm.nih.gov/pubmed/36355805
http://dx.doi.org/10.1182/bloodadvances.2022008209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027508/
https://www.ncbi.nlm.nih.gov/pubmed/36355805
http://dx.doi.org/10.1182/bloodadvances.2022008209

Ejemplares similares